KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Debt to Equity (2017 - 2023)

Bionano Genomics' Debt to Equity history spans 5 years, with the latest figure at $0.08 for Q3 2023.

  • For Q3 2023, Debt to Equity rose 154.5% year-over-year to $0.08; the TTM value through Sep 2023 reached $0.08, up 154.5%, while the annual FY2022 figure was $0.04, N/A changed from the prior year.
  • Debt to Equity for Q3 2023 was $0.08 at Bionano Genomics, up from $0.05 in the prior quarter.
  • Across five years, Debt to Equity topped out at $5.56 in Q4 2019 and bottomed at -$14.44 in Q2 2019.
  • The 5-year median for Debt to Equity is $0.04 (2021), against an average of -$0.53.
  • The largest annual shift saw Debt to Equity tumbled 228.66% in 2020 before it soared 154.5% in 2023.
  • A 5-year view of Debt to Equity shows it stood at $5.56 in 2019, then crashed by 91.63% to $0.47 in 2020, then tumbled by 91.19% to $0.04 in 2021, then decreased by 8.21% to $0.04 in 2022, then skyrocketed by 123.39% to $0.08 in 2023.
  • Per Business Quant, the three most recent readings for BNGO's Debt to Equity are $0.08 (Q3 2023), $0.05 (Q2 2023), and $0.04 (Q1 2023).